The following errors were published in this article.
The following errors were published in this article.
1. On page 2, under Study Design, right column, 2nd paragraph, the first and second sentences are incorrect. These 2 sentences currently read, ''if patients were HCV RNA negative at 12 weeks, the dose of CIFN was reduced to 15 mcg three times weekly for a further 36 weeks. Patients with a greater than 2 log decrease in HCV RNA were continued on daily CIFN/ribavirin for 36 weeks; treatment was discontinued in patients with a less than 2 log decrease in HCV RNA.'' The entire second sentence should be removed and the first sentence should be modified. The below is how the entire paragraph should read:
At 12 weeks, the dose of CIFN was reduced to 15 mcg three times weekly for a further 36 weeks. All patients were followed for 24 weeks after completion of treatment. Patients were provided with the appropriate medication instructions and obtained the study drugs through private pharmacies or other independent providers as dictated by their individual insurance companies. 
